Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program March 12, 2026 — Competitive Grant Program to Offer Individual Grants of Up to $10,000 per Project — — Inaugural Application Cycle Open to Licensed Psychiatric-Mental Health Nurse Practitioners Across Multiple Clinical Settings — — Application Period to Run From March 16, 2026 Through June 1, 2026 —
Baseimmune Announces Strategic Expansion into Fibrosis with Lead Program Targeting Idiopathic Pulmonary Fibrosis (IPF) March 12, 2026 Baseimmune unveils a new multi-pathway immunotherapy strategy, applying its computational protein design platform to develop next-generation therapies for fibrosis. Fibrosis is driven by complex and redundant biological pathways, limiting the effectiveness of single-target approaches. Baseimmune uses advanced computational protein design to target multiple pro-fibrotic pathways simultaneously. Initially focused on IPF, where approved single-target therapies only slow lung function decline. Fibrosis pipeline advancing toward proof-of-concept efficacy readouts in 2026 and 2027. Assembled world-class Scientific Advisory Board: John Cijiang He, Scott L. Friedman, Toby Maher, Paul Noble, and Joel Rurik.
Nature Medicine Study Shows AI Outperforms Therapists on Cognitive Behavioral Therapy March 12, 2026 Randomized, double-blind trial shows Limbic’s clinical reasoning layer turns leading LLMs into mental health specialists, achieving gold-standard clinical performance
NAFFCO Group and Verona Shelters Launch Strategic Joint Venture to Scale Civil and Military Shelter Production Globally March 12, 2026 NAFFCO Group has entered into a Joint Venture Agreement with Verona Shelters to form a strategic partnership dedicated to developing and manufacturing advanced civil defense and military shelter solutions in the United Arab Emirates. The partnership significantly expands global production capacity for protective shelter infrastructure at a time when governments and critical industries are strengthening [...]
Level Access Supercharges Partner Program to Accelerate Digital Accessibility March 12, 2026 IBM, Slalom, Merkle, and more will harness the power of Level Access’s platform to deliver inclusive customer experiences
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure March 12, 2026 Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s [...]
Texas Stock Exchange (TXSE) Selects Options’ AtlasInsight for Next Generation Packet Capture and Real Time Analytics March 11, 2026 Options Technology (Options), the leading provider of financial services infrastructure, today announced that its AtlasInsight platform has been selected by the Texas Stock Exchange (TXSE) to deliver high-fidelity packet capture and real-time analytics across TXSE’s proprietary, world-class trading infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311267175/en/ As TXSE prepares to launch [...]
Xsolla Releases New Industry Report Identifying the Biggest Opportunities for the Future of Video Games for Developers March 11, 2026 The Xsolla Report Reveals How Studios Are Unlocking New Revenue, Reaching Global Audiences, and Building Durable Competitive Advantages
Cognitive Credit AI Sets New Standard for Tech-Enabled Credit Analysis March 11, 2026 Cognitive Credit, the leading provider of specialist data and analytics for corporate credit markets, today announces the launch of Cognitive Credit AI, a new intelligence capability integrated into its existing offering. The new service enables credit investors to generate detailed, context-aware analysis from a library of more than 200,000 official documents and structured financial data [...]
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan March 11, 2026 Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug. The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as well as royalties of up to 20% on sales. The population of available patients eligible for corticorelin treatment associated with peritumoral brain edema is estimated at 60,000 in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually.